Glenmark Pharmaceuticals Limited — Updates, 09-06-2025: Press Release

Glenmark Pharmaceuticals has launched BRUKINSA® (zanubrutinib) in India, targeting five B-cell malignancies including CLL/SLL and mantle cell lymphoma. Developed by BeOne Medicines, this BTK inhibitor offers a differentiated safety and efficacy profile with flexible dosing. The launch strengthens Glenmark’s oncology portfolio and taps into India’s significant hematological cancer market, backed by global approvals in over 70 countries and robust clinical data.